The primary objective of our centre is to translate recent huge advances in the basic understanding of the pathogenesis of coeliac disease to the clinic – to improve disease diagnostics, to implement novel treatments and to identify new therapeutic targets for this common disease.
The secondary objective is to become a clinical research site at the international forefront which will provide optimal patient care and which will be a unique training site for basic scientists and clinicians.
Did you miss our presentation at Coeliac UK?
Oct. 21, 2020 9:24 AM
In February, our research was presented on social media platforms and at the website of Coeliac UK. We also participated in a Q&A, answering questions from patients and the public.
Awards to Lene S. Høydahl for her work on detection of peptide-MHC on gut plasma cells.
Dec. 20, 2019 10:59 AM
Lene S. Høydahl recieved the best research paper 2019 award from the Norwegian Society for Immunology (NSI) and the price for best research paper 2019 from the Department of Biosciences, University of Oslo. Congratulations Lene!
Asbjørn Christophersen and co-authors win price at Oslo University Hospital best paper award 2019
Nov. 28, 2019 11:23 AM
The paper "Distinct phenotype of CD4 + T cells driving celiac disease identified in multiple autoimmune conditions" published in Nature Medicine earlier this year recieved a price as one of six awarded excellent research paper from OUS in the second half of 2019.
Identification of narrow T-cell phenotype in coeliac disease
May 13, 2019 4:06 PM
Post.doc Asbjørn Christophersen has spear-headed the work that lead to identification of a narrow phenotype of gluten specific CD4+ T cells. This cell subset is also present in other autoimmune conditions and could be a target for future disease therapy.
- Longevity, clonal relationship, and transcriptional program of celiac disease-specific plasma cells Oct. 23, 2020 11:00 AM
- An engineered human albumin enhances half-life and transmucosal delivery when fused to protein-based biologics Oct. 15, 2020 11:00 AM
- Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials Sep. 23, 2020 11:00 AM